Category: CAR T-Cell therapy

Home / CAR T-Cell therapy

Categories

CAR T-Cell therapy for lymphoma

Introduction CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional therapies. This has been quite successful in...

CAR T-Cell therapy for leukemia

Introduction CAR T cell therapy is the breakthrough treatment against various kinds of leukemias, particularly B-cell ALL. In this treatment, genetically modified T cells are specifically designed to...

Types of cancer treated with CAR T-Cell therapy

Introduction CAR T cell therapy has really taken off in harnessing the immune system to specifically destroy cancerous cells. After showing tremendous success at first in the treatment of hematologic...

Complete mechanism of CAR T Cell therapy explained

Introduction CAR T cell therapy is a nascent cancer treatment that targets and eliminates cancerous cells by using the body's immune system. Gene modification is done for the expression of chimeric a...

Gamma delta T cells: Latest option in cancer treatment

Two types of T-cells There exist two distinct categories of T cells: αβ T cells and γδ T cells. The previous statement describes a T-cell receptor (TCR) that consists of a heterodimer composed of...

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

CAR T-Cell treatment Chimeric Antigen Receptor (CAR) T-cell treatments, which target antigens that are unique to cancer, have shown amazing results in curing leukemia and lymphoma that has not respon...

Disruption of CD5 on CAR T Cells Enhances the Effectiveness of Anti-Tumor Treatment

CAR T-Cell therapy in the treatment of cancer A preclinical study conducted by researchers at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center suggests that the...

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignan...

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

May 2024: The Food and Drug Administration has granted approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory mantle c...

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

June 2024: The chances of getting secondary blood cancers after CAR-T cell therapy, a cell-based cancer treatment that got a lot of attention in 2017 for being effective against hard-to-treat blood ca...

Scan the code